Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Duggan

Orthopaedic Surgery Foothill Ranch, CA Doctor of Osteopathy

NPI 1750575437 CMS profile 1296576

26700 Towne Centre Dr, Suite 115, Foothill Ranch, CA 92610

Open in the dashboard

General payments

$3,914

44 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Duggan of Foothill Ranch, CA is reported in the CMS Open Payments database as having received $3,914 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $870 10
2024 General $507 10
2023 General $656 8
2021 General $318 5
2020 General $1,363 2
2019 General $199 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Duggan
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Daniel Duggan were reported at $870. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Daniel Duggan Orthopaedic Surgery median Middle half National median
2019 $199 $644 $140–$2,844 $163
2020 $1,363 $312 $75–$1,860 $114
2021 $318 $520 $117–$2,495 $132
2022 $0 $598 $128–$2,731 $149
2023 $656 $461 $128–$2,264 $160
2024 $507 $497 $134–$2,475 $164
2025 $870 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,506 17 payments
  2. Micromed Inc $1,336 1 payment
  3. Zimmer Biomet Holdings, Inc. $260 5 payments
  4. Miach Orthopaedics, Inc. $228 1 payment
  5. Globus Medical, Inc. $173 5 payments
  6. Orthalign Inc $112 1 payment
  7. AbbVie, Inc. $92 5 payments
  8. Medtronic USA, Inc. $46 2 payments
  9. Smith+Nephew, Inc. $36 1 payment
  10. Paragon 28, Inc. $27 1 payment
  11. Other $98 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,578 43 payments
  2. Education $1,336 1 payment
Products named General payments · program years 2019–2025
  1. PANGEA $359 3 payments
  2. GAMMA $265 3 payments
  3. AXSOS Trauma & Extremeties $184 3 payments
  4. Comprehensive Shoulder System $181 2 payments
  5. T2 ALPHA $157 1 payment
  6. ASNIS $144 1 payment
  7. ORTHALIGN PLUS $112 1 payment
  8. NA $106 1 payment
  9. ALLODERM $92 5 payments
  10. AXSOS Locking Plates $56 1 payment
  11. Other $525 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

249

Median for Orthopedic Surgery: 203

Drug cost

$8,051

Median for Orthopedic Surgery: $1,433

Branded share of claims

52.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 28 $7,043
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 76 $549
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $198
Cephalexin Generic 44 $134
Tramadol Hcl Generic 31 $63
Meloxicam Generic 44 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$75,345

Of which drugs: $11,683

Medicare patients

176

Average age 75

Services billed

3,628

107 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 73%
High blood pressure 70%
Depression 27%
Diabetes 26%
Ischemic heart disease 24%
Osteoporosis 23%
Chronic kidney disease 21%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 Office 24 2,475 $10,094
Injection, methylprednisolone sodium succinate, up to 40 mg J2920 Office 29 38 $112
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 36 386 $82

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record